December 22, 2014 11:45 AM ET


Company Overview of Emcure Pharmaceuticals Limited

Company Overview

Emcure Pharmaceuticals Limited develops, manufactures, and markets various pharmaceutical products worldwide. It provides calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology under the Asomex, Metpure, S-Numlo, Eslo, Lomoh, Elaxim, Velix, and Atorec brands; haematinics and iron combinations, progestogen, and simi combinations for gynecology under the brand names of Orofer-XT, Orofer-S, Encicarb, Ferium-XT, and Feronia-XT; and anti-infective products comprising cephalosporins and ampicillin under the Zostum, Merotec, Netromax, and Augpen brand names. The company also offers vitamins, minerals, and nutrients, such...

Emcure House

T-184, M.I.D.C.


Pune,  411026


Founded in 1981

8,570 Employees


91 20 2712 0084


91 20 3061 0111

Key Executives for Emcure Pharmaceuticals Limited

Managing Director
Age: 63
Chief Financial Officer
Age: 37
Chief Operating Officer and Executive Director
Age: 62
Chief Executive Officer of Gennova Biopharmaceuticals Limited
Age: 47
Managing Director of Zuventus Healthcare Limited
Age: 50
Compensation as of Fiscal Year 2014.

Emcure Pharmaceuticals Limited Key Developments

Cipla Ltd, Strides Arcolab Ltd, Mylan Laboratories Ltd and Emcure Pharmaceuticals Ltd Sign Licensing Deals with Gilead Sciences Inc. to Sell a Low-Cost Version of its $1,000-a-Day Hepatitis C Drug Sovaldi

Cipla Ltd, Strides Arcolab Ltd, Mylan Laboratories Ltd. and Emcure Pharmaceuticals Ltd. are among six generic drug makers that are likely to sign licensing deals with Gilead Sciences Inc. to sell a low-cost version of its $1,000-a-day Hepatitis C drug Sovaldi. The licensing agreements will allow the generic drug companies to make and sell copies of the expensive pill for low- and middle-income countries at lower prices. By signing the licensing agreements with generic drug makers, Gilead is responding to criticism from governments and advocacy groups about the high pricing of the drug that has put it beyond the reach of most patients, particularly those in developing nations. The once-a-day pill used in combination with other antivirals is, however, the most effective therapy to counter Hepatitis C, which kills about 350,000 people a year globally.

Sanofi Partners with Emcure Pharmaceuticals for Marketing and Distribution of its Oncology Portfolio in India

Sanofi announced that it has entered into a marketing and distribution agreement with Emcure Pharmaceuticals for its oncology portfolio in India. As per the agreement, while Sanofi will continue to own its oncology range - comprising 4 brands namely Taxotere, Jevtana, Fludara and Fasturtec, Emcure will market and distribute these brands through its Specialty Unit.

Seven Companies Sign Sub-Licensing Agreements with Medicines Patent Pool

Seven subcontracts have been signed licensing agreements with the Switzerland-based Medicines Patent Pool (MPP) to manufacture two antiretroviral drugs. The agreements involve Aurobindo, Emcure (both India), and Desano (China) manufacturing a generic version of Bristol Myers Squibb (BMS, US)'s atazanavir. The manufacturers, including Cipla, Laurus Labs, Micro Labs (all three India), and Mylan (US), have also signed agreements to manufacture ViiV Healthcare (UK)'s dolutegravir. BMS added atazanavir to the MPP in December 2013 and ViiV Healthcare included dolutegravir in the pool in April.

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Emcure Pharmaceuticals Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at